-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly presented its first batch of clinical data on developing next-generation FRα antibody-conjugated drugs for platinum-sensitive ovarian cancer at the 2026 European Society of Medical Oncology Annual Meeting.

Zhitongcaijing·10/24/2026 06:41:04
Listen to the news
Eli Lilly presented its first batch of clinical data on developing next-generation FRα antibody-conjugated drugs for platinum-sensitive ovarian cancer at the 2026 European Society of Medical Oncology Annual Meeting.